This compounded formulation of Estriol/Estradiol [80%-20%] 1 - 2.5 mg/Progesterone 100 - 200 mg Slow Release Capsules is a potent combination of hormones designed to treat a variety of conditions related to reproductive health. Estriol and Estradiol, which make up 80% and 20% of the formulation respectively, are essential hormones for regulating the menstrual cycle, fertility, and other reproductive functions. Progesterone, present in the range of 100 - 200 mg, is a crucial hormone for maintaining a healthy pregnancy and regulating the menstrual cycle.

This formulation is particularly beneficial for individuals suffering from menopausal symptoms, endometriosis, and uterine fibroids. It can also be used to regulate the menstrual cycle and improve fertility. The dosage of Estriol/Estradiol and Progesterone can be adjusted based on the individual patient's needs, ensuring a personalized treatment approach.

What sets this formulation apart is its slow-release design. The capsules are formulated with Methocel E4M, a type of controlled-release polymer. This innovative design allows for the gradual release of the encapsulated medication or active ingredient over an extended period of time. This sustained release offers prolonged therapeutic effects, reduces the frequency of dosing, and improves patient compliance, particularly for medications requiring a controlled and prolonged release profile.

As an oral medication, this formulation provides a steady and consistent release of hormones over time, ensuring a stable hormonal environment. It is crucial to follow the instructions of your healthcare provider when taking this medication to ensure optimal results and minimize potential side effects.

This formulation is an effective treatment option for a variety of disease states, offering the potential to significantly improve the quality of life for those suffering from menopausal symptoms, endometriosis, and uterine fibroids. If you have any questions about this formulation, please do not hesitate to reach out for further information.

This compounded formulation of Estriol/Estradiol [80%-20%] 1 - 2.5 mg/Progesterone 100 - 200 mg Slow Release Capsules is specifically designed to provide sustained therapeutic effects over an extended period of time. The formulation is encapsulated with Methocel E4M, a controlled-release polymer, which allows for a gradual release of the active ingredients. This slow release mechanism reduces the frequency of dosing and improves patient compliance, particularly beneficial for medications requiring a controlled and prolonged release profile.

The primary use of this formulation is to alleviate menopausal symptoms such as hot flashes, night sweats, and vaginal dryness. It is also utilized in the prevention of postmenopausal osteoporosis and in the treatment of certain types of breast cancer in postmenopausal women. Additionally, this formulation may be prescribed for the treatment of endometriosis and uterine fibroids.

It is crucial for patients to be aware that this formulation may interact with other medications, including certain antibiotics, antifungals, and anticoagulants. Interactions may also occur with certain herbal supplements, such as St. John's wort. Therefore, it is essential for patients to inform their healthcare provider of all medications and supplements they are currently taking before starting this formulation.

Patients should also be cognizant of potential side effects, which may include nausea, vomiting, headache, breast tenderness, and changes in menstrual bleeding. More serious risks may include an increased risk of blood clots, stroke, and heart attack. Any occurrence of these side effects should be immediately reported to a healthcare provider.

This formulation is contraindicated for use by pregnant or breastfeeding women, or by women who have a history of stroke, blood clots, or heart attack. Patients with a history of liver or kidney disease, high blood pressure, or diabetes should also inform their healthcare provider before starting this medication.

If you have any questions or concerns about this formulation, please do not hesitate to reach out to your healthcare provider for further information and guidance.

This compounded formulation combines estriol and estradiol in an 80%-20% ratio, with 1-2.5 mg of estriol, 2-5 mg of estradiol, and 100-200 mg of progesterone. These components are encapsulated in slow-release capsules, designed with Methocel E4M, a controlled-release polymer. This advanced technology ensures the gradual release of the active ingredients over an extended period, providing sustained therapeutic effects and improved patient compliance due to reduced dosing frequency.

Estriol and estradiol are hormones naturally produced by the body, playing crucial roles in regulating the menstrual cycle and alleviating menopausal symptoms. Progesterone, another hormone integral to menstrual cycle regulation, is also included in this formulation. It is commonly used in the treatment of conditions such as endometriosis and uterine fibroids.

This formulation is typically prescribed for the management of various disease states, including menopausal symptoms, endometriosis, and uterine fibroids. It is essential to take these capsules as directed by your healthcare provider, ideally with food and at the same time each day. This ensures consistent hormone release and optimal therapeutic benefits. Swallow the capsules whole without breaking or crushing them.

Continuing the medication for the full duration of the treatment is crucial, as premature discontinuation can lead to a recurrence of symptoms. If you have any questions or need further clarification about this formulation, its mechanism of action, or how it can help manage your symptoms, please do not hesitate to reach out. We are here to assist you in understanding your medication better.

This compounded formulation of Estriol/Estradiol [80%-20%] 1 - 2.5 mg/Progesterone 100 - 200 mg Slow Release Capsules, formulated with Methocel E4M, is designed to gradually release the encapsulated medication over an extended period of time. This controlled-release mechanism offers sustained therapeutic effects, reduces dosing frequency, and improves patient compliance, particularly for medications requiring a controlled and prolonged release profile.

Aside from its primary use, this formulation can also be employed to manage a variety of conditions. It can be used to treat premenstrual dysphoric disorder (PMDD), premenstrual syndrome (PMS), and dysmenorrhea, providing relief from the associated symptoms. For postmenopausal women undergoing estrogen therapy, this formulation can be used to reduce the risk of endometrial hyperplasia, a condition characterized by the thickening of the lining of the uterus.

Furthermore, this formulation may be beneficial for women with a family history of ovarian or breast cancer. It can be used as a preventive measure to reduce the risk of these cancers. Additionally, it may also be used to reduce the risk of cardiovascular disease in postmenopausal women, contributing to overall heart health.

It is important to consult with a healthcare provider to understand the potential benefits and risks associated with the use of this formulation for these conditions. Always seek professional medical advice before starting any new medication or treatment plan.